N E W P R O D U C T

PALO ALTO, Calif--ALZA Corporation and U.S. Bioscience, Inc. haveannounced the availability of Ethyol (amifostine), which was FDAapproved in December, 1995.

The agent is indicated to reduce the cumulative renal toxicityassociated with repeated administration of cisplatin (Platinol)in patients with advanced ovarian cancer or non-small-cell lungcancer. In these settings, the clinical data do not suggest thatthe effectiveness of cisplatin-based chemotherapy regimens isaltered by use of Ethyol.

There are at present only limited data on the influence of Ethyolon the efficacy of chemotherapy in other settings; therefore,Ethyol should not be given to patients in other settings wherechemotherapy can produce a significant survival benefit or cure(eg, certain malignancies of germ cell origin), except in thecontext of a clinical study.

ALZA will be responsible for US sales and marketing of Ethyol.